Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) and its progressive form nonalcoholic steatohepatitis (NASH) comprise a spectrum of chronic liver diseases in the global population that can lead to end-stage liver disease and hepatocellular carcinoma (HCC). NAFLD is closely linked to the metabolic syndrome, and comorbidities such as type 2 diabetes, obesity and insulin resistance aggravate liver disease, while NAFLD promotes cardiovascular risk in affected patients. The pathomechanisms of NAFLD are multifaceted, combining hepatic factors including lipotoxicity, mechanisms of cell death and liver inflammation with extrahepatic factors including metabolic disturbance and dysbiosis. Nuclear receptors (NRs) are a family of ligand-controlled transcription factors that regulate glucose, fat and cholesterol homeostasis and modulate innate immune cell functions, including liver macrophages. In parallel with metabolic derangement in NAFLD, altered NR signaling is frequently observed and might be involved in the pathogenesis. Therapeutically, clinical data indicate that single drug targets thus far have been insufficient for reaching patient-relevant endpoints. Therefore, combinatorial treatment strategies with multiple drug targets or drugs with multiple mechanisms of actions could possibly bring advantages, by providing a more holistic therapeutic approach. In this context, peroxisome proliferator-activated receptors (PPARs) and other NRs are of great interest as they are involved in wide-ranging and multi-organ activities associated with NASH progression or regression. In this review, we summarize recent advances in understanding the pathogenesis of NAFLD, focusing on mechanisms of cell death, immunometabolism and the role of NRs. We outline novel therapeutic strategies and discuss remaining challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metabolic processes in both hepatocytes and non-parenchymal liver cells are modulated by nuclear receptors”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · cited 1×
“MPT-driven necrosis, as a type of regulated cell death, is caused by toxins- or oxidative stress-induced cell microenvironment disturbances, which lead to the sudden disability of mitochondrial membrane potential and subsequent cell membrane rupture [41].”
BackgroundGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased profoundly over the last decades-to date, representing the most common cause of chronic liver disease worldwide and numbers are expected to increase even further [1,2].”
BackgroundObesity induces a phenotypic switch in adipose tissue macrophage polarization
Lumeng, C. N., Bodzin, J. L., & Saltiel, A. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29881 · Cited by 4,664 · cited 1×
“The accumulation of pro-inflammatory macrophages in lipid-enriched liver has been identified as a cause of obesity-induced chronic inflammation [81].”
BackgroundMechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354 · cited 2×
“As awareness of NAFLD is increasing globally [206], ongoing preclinical and clinical studies provided various pathomechanistic insights into disease development and progression, identifying many new potential drug targets [24,207,208].”
BackgroundPyroptosis: host cell death and inflammation
Bergsbaken, T., Fink, S. L., & Cookson, B. T. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2070 · Cited by 3,183 · cited 1×
“Morphologically, the pyroptotic features include ion influx, cell swelling, membrane pore formation, mitochondrial depolarization, chromatin condensation and membrane rupture, resulting in cytoplasmic secretion of interleukin (IL)-1β, IL-18 and other contents, thereby triggering inflammation [61].”
BackgroundVernon, G., Baranova, A., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,074 · cited 6×
“Sci. 2022, 23, 2668. https://doi.org/10.3390/ijms23052668 https://www.mdpi.com/journal/ijms HCC in the context of NAFLD can occur even in the absence of cirrhosis [7].”
BackgroundInfluentialAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Macrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Inflammation, metaflammation and immunometabolic disorders
Hotamisligil, G. S. (2017) · Nature · doi:10.1038/nature21363 · Cited by 2,570 · cited 1×
“For instance, macrophages were identified as key drivers in the regulation of inflammationassociated insulin signaling [20,21].”
BackgroundEvolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548 · cited 1×
“In this context, combinatorial therapeutic strategies targeting multiple pathways in parallel appear attractive and potentially bear significant advantages over single drug treatments (Figure 2) [210,211].”
BackgroundEstes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
Molecular mechanisms of necroptosis: an ordered cellular explosion
Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., & Kroemer, G. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2970 · Cited by 2,382 · cited 1×
“Unlike nuclear coagulation and cell shrinkage as seen in apoptosis, necrosis is characterized by swelling and deficiency of plasma membrane integrity [42,43].”
BackgroundCell death: a review of the major forms of apoptosis, necrosis and autophagy
D’Arcy, M. S. (2019) · Cell Biology International · doi:10.1002/cbin.11137 · Cited by 2,307 · cited 1×
“Unlike nuclear coagulation and cell shrinkage as seen in apoptosis, necrosis is characterized by swelling and deficiency of plasma membrane integrity [42,43].”
BackgroundEkstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · cited 2×
“Administration of OCA for 72 weeks in adult NASH patients in a multicentre, randomised, placebo-controlled phase 2 trial effectively improved histological disease features (FLINT, ClinicalTrials.gov (accessed on 28 December 2021) Identifier NCT01265498) [231].”
BackgroundBraissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217 · cited 1×
“On the contrary, PPAR γ is overexpressed in white adipose tissue and steatotic liver [124,125].”
BackgroundTranscriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation
Xue, J., Schmidt, S. V., Sander, J., Draffehn, A., Krebs, W., Quester, I., De Nardo, D., Gohel, T. D., Emde, M., Schmidleithner, L., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.01.006 · Cited by 2,210
Tissue-Resident Macrophage Enhancer Landscapes Are Shaped by the Local Microenvironment
Lavin, Y., Winter, D., Blecher-Gonen, R., David, E., Keren-Shaul, H., Merad, M., Jung, S., & Amit, I. (2014) · Cell · doi:10.1016/j.cell.2014.11.018 · Cited by 2,167 · cited 1×
“In the context of diabetes, endogenous FA synthesis can modulate the functional phenotype of macrophages [90].”
BackgroundNecroptosis, pyroptosis and apoptosis: an intricate game of cell death
Bertheloot, D., Latz, E., & Franklin, B. S. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00630-3 · Cited by 2,166 · cited 3×
“Generally, TNF-α, oxidative stress (OS) and mammalian target of rapamycin (mTOR)/RAC serine/threonine-protein kinase (Akt) signaling pathway, regarded as necroptotic stimuli can activate three key kinases in the necroptosis pathway through a phosphorylation sequence: RIPK1, RIPK3 and MLKL. Phosphorylation of MLKL lead…”
BackgroundWilliams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148 · cited 1×
“The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased profoundly over the last decades-to date, representing the most common cause of chronic liver disease worldwide and numbers are expected to increase even further [1,2].”
BackgroundFGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125 · cited 1×
“FGF21 agonists are mainly active in hepatic and adipose tissue due to FGF receptor expression profiles and tissue distribution of the co-receptor β-Klotho [225,226].”
BackgroundMacrophage-specific PPARγ controls alternative activation and improves insulin resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Goforth, M. H., Morel, C. R., Subramanian, V., Mukundan, L., Eagle, A. R., Vats, D., Brombacher, F., Ferrante, A. W., et al. (2007) · Nature · doi:10.1038/nature05894 · Cited by 2,107
The Enzymes, Regulation, and Genetics of Bile Acid Synthesis
Russell, D. W. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161712 · Cited by 2,069 · cited 1×
“The activation of PPAR β/δ is related to the induction of anti-inflammatory signals and anti-inflammatory phenotype in KCs, which reduced metabolic disorders in the liver [144,145].”
BackgroundOverview of the IL ‐1 family in innate inflammation and acquired immunity
Dinarello, C. A. (2018) · Immunological Reviews · doi:10.1111/imr.12621 · Cited by 1,866 · cited 1×
“of DAMPs, participating in necroptosis regulation [56].”
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855 · cited 1×
“HCC in the context of NAFLD can occur even in the absence of cirrhosis [7].”
BackgroundTargeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
Gong, T., Liu, L., Jiang, W., & Zhou, R. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0215-7 · Cited by 1,672 · cited 1×
“DAMPs trigger and exacerbate the inflammatory modulation via binding to the surface receptors of innate immune cells [48,49].”
BackgroundMaeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.9.2094 · Cited by 1,659
Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting
Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., & Wahli, W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6223 · Cited by 1,649
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392 · cited 1×
“Numerous disease-promoting mechanisms have been identified, such as genetic risk profile, environmental factors, metabolic dysregulation, inflammation, intestinal dysbiosis, molecular factors (oxidative stress, lipotoxicity, mechanisms of cell death) and fibrogenesis (Figure 1) [12].”
BackgroundRole of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease
Chen, Z., Tian, R., She, Z., Cai, J., & Li, H. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.02.025 · Cited by 1,279 · cited 1×
“Furthermore, oxidative stress is significantly involved in the NASH pathogenesis [28,29] (Figures 1 and 2).”
BackgroundYounossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277 · cited 2×
“gov (accessed on 28 December 2021) Identifier NCT02548351) [234].”
BackgroundShigella flexneri induces apoptosis in infected macrophages
Zychlinsky, A., Prevost, M. C., & Sansonetti, P. J. (1992) · Nature · doi:10.1038/358167a0 · Cited by 1,262 · cited 1×
“Pyroptosis has been described as a lytic inflammation-regulated cell death and was initially found to occur in macrophages infected with bacteria [59,60].”
BackgroundNon-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Yki-Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,259 · cited 1×
“Of note, NAFLD is not only a consequence of fat accumulation but might also be a major driver for the development of the metabolic syndrome and its complications [3,4].”
BackgroundLi, J., McQuade, T., Siemer, A. B., Napetschnig, J., Moriwaki, K., Hsiao, Y.-S., Damko, E., Moquin, D., Walz, T., McDermott, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.019 · Cited by 1,222 · cited 2×
“Recent discoveries from murine models indicate that RIPK3-modulated necroptosis not only participates in alcohol-induced liver damage, but it can also cause NASH [53,54].”
BackgroundIdentification of a nuclear receptor that is activated by farnesol metabolites
Forman, B. M., Goode, E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Lamph, W. W., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90530-8 · Cited by 1,210 · cited 1×
“FXR is expressed in many tissues, including kidneys, stomach, intestine, gall bladder, liver, and adipose tissue [176].”
BackgroundNuclear Receptors, RXR, and the Big Bang
Evans, R. M., & Mangelsdorf, D. J. (2014) · Cell · doi:10.1016/j.cell.2014.03.012 · Cited by 1,200 · cited 1×
“In humans, 48 NRs were identified thus far [122].”
BackgroundMacrophage Immunometabolism: Where Are We (Going)?
Van den Bossche, J., O’Neill, L. A., & Menon, D. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.03.001 · Cited by 1,163
Akt Signaling Pathway in Macrophage Activation and M1/M2 Polarization
Vergadi, E., Ieronymaki, E., Lyroni, K., Vaporidi, K., & Tsatsanis, C. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601515 · Cited by 1,148
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.022 · Cited by 1,110 · cited 3×
“Interestingly, free cholesterol is elevated in NASH livers in both humans and mice and has been proposed to be a lipotoxic DAMP, inducing NLRP3 activation and pyroptosis in Kupffer cells [40,74,75].”
BackgroundHepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M., Burgart, L. J., Lindor, K. D., & Gores, G. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00907-7 · Cited by 1,085 · cited 1×
“Clinical studies have established that hepatocellular apoptosis in NASH patients is more severe than in patients with exclusive steatosis, and correlated with increased fibrosis and inflammation [35].”
BackgroundNeuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 1×
“Lipid deposition in hepatocytes leads to lipotoxicity, mitochondrial dysfunction, production of reactive oxygen species (ROS), and endoplasmic reticulum (ER) stress [25].”
BackgroundRatziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031 · cited 1×
“dietary obesity model corrected bodyweight and diabetes [228].”
BackgroundTyagi, S., Gupta, P., Saini, A., Kaushal, C., & Sharma, S. (2011) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/2231-4040.90879 · Cited by 1,017 · cited 1×
“In addition, PPAR γ is also involved in extrahepatic effects regulating adipocyte differentiation, storage of fatty acids and glucose metabolism [150].”
BackgroundNovel Markers to Delineate Murine M1 and M2 Macrophages
Jablonski, K. A., Amici, S. A., Webb, L. M., Ruiz-Rosado, J. D. D., Popovich, P. G., Partida-Sanchez, S., & Guerau-de-Arellano, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0145342 · Cited by 978 · cited 1×
“It was shown that macrophage populations exhibit phenotypic heterogeneity and high plasticity based on their environment and intracellular signal transduction [83,84].”
BackgroundLeclercq, S., Matamoros, S., Cani, P. D., Neyrinck, A. M., Jamar, F., Stärkel, P., Windey, K., Tremaroli, V., Bäckhed, F., Verbeke, K., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415174111 · Cited by 972 · cited 2×
“Indeed, compared with naïve macrophages and pro-inflammatory macrophages, IL-4 induced anti-inflammatory macrophages to exert higher activities of lipolysis, fatty acid oxidation (FAO) and oxidative phosphorylation (OXPHOS) [92].”
BackgroundChávez-Talavera, O., Tailleux, A., Lefebvre, P., & Staels, B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.055 · Cited by 970
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice
Zhang, Y., Lee, F. Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F. J., Willson, T. M., & Edwards, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506982103 · Cited by 953 · cited 1×
“In addition, FXR deficiency may also lead to insulin resistance [179,180].”
BackgroundTriggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941 · cited 1×
“phenotypes by interfering with their metabolism and thus reprograms their functionality, further contributing to steatohepatitis [77].”
BackgroundCaspases in Cell Death, Inflammation, and Pyroptosis
Kesavardhana, S., Malireddi, R. K. S., & Kanneganti, T.-D. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-073119-095439 · Cited by 923 · cited 1×
“Via these above pathways, pyroptosis can promote the accumulation of immune cells and the activation of adaptive immune responses [70].”
BackgroundFarnesoid X receptor is essential for normal glucose homeostasis
Ma, K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25604 · Cited by 882
Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells
Scott, C. L., Zheng, F., De Baetselier, P., Martens, L., Saeys, Y., De Prijck, S., Lippens, S., Abels, C., Schoonooghe, S., Raes, G., et al. (2016) · Nature Communications · doi:10.1038/ncomms10321 · Cited by 860 · cited 2×
“KCs are of embryonic origin and maintained locally by self-renewal, as opposed to monocyte-derived macrophages (MoMFs) originating from the bone marrow [95].”
BackgroundDAMPs, PAMPs, and LAMPs in Immunity and Sterile Inflammation
Zindel, J., & Kubes, P. (2020) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032847 · Cited by 856 · cited 1×
“DAMPs trigger and exacerbate the inflammatory modulation via binding to the surface receptors of innate immune cells [48,49].”
BackgroundYounossi, Z., Stepanova, M., Ong, J. P., Jacobson, I. M., Bugianesi, E., Duseja, A., Eguchi, Y., Wong, V. W., Negro, F., Yilmaz, Y., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.05.057 · Cited by 806
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2036205 · Cited by 801
PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD
Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778 · cited 1×
“PPARα is predominantly involved in upregulation of hepatic gene expression levels related to gluconeo- and ketogenesis, mitochondrial and peroxisomal β-oxidation, as well as fatty acid binding and transportation [130].”
BackgroundCell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.018 · Cited by 759 · cited 1×
“Major histopathological and pathophysiological features of NASH include immune cell infiltration, intracellular lipid accumulation and cell swelling, all of which are precursors of programmed hepatocyte death [39].”
BackgroundAdvancing the global public health agenda for NAFLD: a consensus statement
Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., et al. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00523-4 · Cited by 757 · cited 1×
“As awareness of NAFLD is increasing globally [206], ongoing preclinical and clinical studies provided various pathomechanistic insights into disease development and progression, identifying many new potential drug targets [24,207,208].”
BackgroundSelf-citationToll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1β in Mice
Miura, K., Kodama, Y., Inokuchi, S., Schnabl, B., Aoyama, T., Ohnishi, H., Olefsky, J. M., Brenner, D. A., & Seki, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.052 · Cited by 741
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3760 · Cited by 738 · cited 1×
“The gut specific FXR agonist feraxamine showed improvement of obesity, insulin resistance and steatosis in obese mice [183].”
BackgroundLiver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
Montagner, A., Polizzi, A., Fouché, E., Ducheix, S., Lippi, Y., Lasserre, F., Barquissau, V., Régnier, M., Lukowicz, C., Benhamed, F., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310798 · Cited by 736
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
Lonardo, A., Nascimbeni, F., Mantovani, A., & Targher, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.021 · Cited by 736 · cited 1×
“Of note, NAFLD is not only a consequence of fat accumulation but might also be a major driver for the development of the metabolic syndrome and its complications [3,4].”
BackgroundMacrophages, Immunity, and Metabolic Disease
McNelis, J. C., & Olefsky, J. M. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.010 · Cited by 720 · cited 1×
“For instance, macrophages were identified as key drivers in the regulation of inflammationassociated insulin signaling [20,21].”
BackgroundRivera, C. A., Adegboyega, P., van Rooijen, N., Tagalicud, A., Allman, M., & Wallace, M. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.019 · Cited by 693
Salmonella induces macrophage death by caspase‐1‐dependent necrosis
Brennan, M. A., & Cookson, B. T. (2000) · Molecular Microbiology · doi:10.1046/j.1365-2958.2000.02103.x · Cited by 674 · cited 1×
“Pyroptosis has been described as a lytic inflammation-regulated cell death and was initially found to occur in macrophages infected with bacteria [59,60].”
BackgroundCurrent and future pharmacological therapies for NAFLD/NASH
Sumida, Y., & Yoneda, M. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-017-1415-1 · Cited by 667 · cited 1×
“Free fatty acids (FFAs) can activate the toll-like receptor (TLR) 4 on macrophages, thereby activating the NF-κB pathway and inducing pro-inflammatory cytokine release [82].”
BackgroundBile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M., & Trauner, M. (2017) · Hepatology · doi:10.1002/hep.28709 · Cited by 634 · cited 2×
“FGF19 is an intestinal expressed molecule involved in various metabolic pathways, including suppression of bile acid synthesis, enterohepatic bile acid circulation and cholesterol demand [221].”
BackgroundLocal Proliferation of Macrophages Contributes to Obesity-Associated Adipose Tissue Inflammation
Amano, S. U., Cohen, J. L., Vangala, P., Tencerova, M., Nicoloro, S. M., Yawe, J. C., Shen, Y., Czech, M. P., & Aouadi, M. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.11.017 · Cited by 613 · cited 1×
“In contrast, anti-inflammatory macrophages obtain energy supply through FA degradation [91].”
BackgroundMitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis
Marí, M., Caballero, F., Colell, A., Morales, A., Caballeria, J., Fernandez, A., Enrich, C., Fernandez-Checa, J. C., & García-Ruiz, C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.07.006 · Cited by 608 · cited 1×
“Of note, mitochondrial oxidative stress caused by the accumulation of free cholesterol enhanced the hepatic sensitivity to cytokine-induced cell death [32].”
BackgroundGuerre-Millo, M., Gervois, P., Raspé, E., Madsen, L., Poulain, P., Derudas, B., Herbert, J.-M., Winegar, D. A., Willson, T. M., Fruchart, J.-C., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.22.16638 · Cited by 605
Deletion of NEMO/IKKγ in Liver Parenchymal Cells Causes Steatohepatitis and Hepatocellular Carcinoma
Luedde, T., Beraza, N., Kotsikoris, V., van Loo, G., Nenci, A., De Vos, R., Roskams, T., Trautwein, C., & Pasparakis, M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.016 · Cited by 597
Inflammasome activation and function in liver disease
Szabo, G., & Petrasek, J. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.94 · Cited by 597 · cited 1×
“Hence, IL-18 tends to prevent tissue damage from overreactive immune responses [72,73].”
BackgroundRemmerie, A., Martens, L., Thoné, T., Castoldi, A., Seurinck, R., Pavie, B., Roels, J., Vanneste, B., De Prijck, S., Vanhockerhout, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.004 · Cited by 592 · cited 1×
“More recent evidence suggests that Kupffer cells are lost during experimental steatohepatitis and replenished by monocyte derived Kupffer cells with similar, albeit more pro-inflammatory gene expression profiles [96,97].”
BackgroundCirculating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding
Markan, K. R., Naber, M. C., Ameka, M. K., Anderegg, M. D., Mangelsdorf, D. J., Kliewer, S. A., Mohammadi, M., & Potthoff, M. J. (2014) · Diabetes · doi:10.2337/db14-0595 · Cited by 590 · cited 1×
“FGF21 agonists are mainly active in hepatic and adipose tissue due to FGF receptor expression profiles and tissue distribution of the co-receptor β-Klotho [225,226].”
BackgroundLiver X receptors in lipid metabolism: opportunities for drug discovery
Hong, C., & Tontonoz, P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4280 · Cited by 587 · cited 1×
“Although several selective LXR agonists (such as Dessinosterol, GW6340 and LXRb agonist LXR-623) have been investigated, more data are required before therapeutical application in NAFLD [200].”
BackgroundApoptosis and necroptosis in the liver: a matter of life and death
Schwabe, R. F., & Luedde, T. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0065-y · Cited by 582 · cited 2×
“Apart from apoptosis, necrosis is a driver of NASH initiation and progression [36].”
BackgroundRecent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573 · cited 1×
“A vicious cycle ensues, as inflammatory cytokines produced by immune cells increase metabolic dysregulation in adipose tissue and in the liver, resulting in additional stress-induced cell death [26].”
BackgroundImmune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573 · cited 2×
“The progression of steatosis to NASH is hallmarked by liver inflammation, including infiltration of numerous different immune cell populations, such as myeloid cells, B cells, T cells and NKT cells [76].”
BackgroundGulick, T., Cresci, S., Caira, T., Moore, D. D., & Kelly, D. P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11012 · Cited by 560 · cited 1×
“In mice, MCD diet-induced steatohepatitis and fibrosis was reversed by applying the PPARα agonist WY-1 [127,135].”
BackgroundIntestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K. W., Shi, J., Brocker, C. N., Desai, D., Amin, S. G., Bisson, W. H., et al. (2015) · Nature Communications · doi:10.1038/ncomms10166 · Cited by 559 · cited 1×
“In obesity, modulation of FXR signaling proved to have beneficial effects [177].”
BackgroundGaul, S., Leszczynska, A., Alegre, F., Kaufmann, B., Johnson, C. D., Adams, L. A., Wree, A., Damm, G., Seehofer, D., Calvente, C. J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.041 · Cited by 552 · cited 2×
“Mechanistically, hepatocyte pyroptosis was induced by inflammasome activation and interestingly, this was mediated by stellate cells engulfing extracellular NLRP3 inflammasome particles [64].”
BackgroundSanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio, D., Kundu, S., Noviello, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31785-9 · Cited by 550
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Khan, R. S., Bril, F., Cusi, K., & Newsome, P. N. (2019) · Hepatology · doi:10.1002/hep.30429 · Cited by 542
PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice
Wang, Y., Nakajima, T., Gonzalez, F. J., & Tanaka, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062061 · Cited by 540 · cited 1×
“The activation of SCD1 eventually favors the liver protection via a positive feedback regulation [140,141].”
BackgroundArroyave-Ospina, J. C., Wu, Z., Geng, Y., & Moshage, H. (2021) · Antioxidants · doi:10.3390/antiox10020174 · Cited by 527 · cited 1×
“Furthermore, oxidative stress is significantly involved in the NASH pathogenesis [28,29] (Figures 1 and 2).”
BackgroundThe Farnesoid X Receptor: A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism
Claudel, T., Staels, B., & Kuipers, F. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000178994.21828.a7 · Cited by 504
The Role of Cholesterol in the Pathogenesis of NASH
Ioannou, G. N. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.11.008 · Cited by 498 · cited 1×
“Another lipotoxic molecule in NASH is free cholesterol [102,103].”
BackgroundMicrobiota-induced obesity requires farnesoid X receptor
Parséus, A., Sommer, N., Sommer, F., Caesar, R., Molinaro, A., Ståhlman, M., Greiner, T. U., Perkins, R., & Bäckhed, F. (2017) · Gut · doi:10.1136/gutjnl-2015-310283 · Cited by 474
Kupffer Cell Engulfment of Apoptotic Bodies Stimulates Death Ligand and Cytokine Expression
Canbay, A., Feldstein, A. E., Higuchi, H., Werneburg, N., Grambihler, A., Bronk, S. F., & Gores, G. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50472 · Cited by 470
Gut microbiome, liver immunology, and liver diseases
Wang, R., Tang, R., Li, B., Ma, X., Schnabl, B., & Tilg, H. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00592-6 · Cited by 466 · cited 2×
“Indeed, compared with naïve macrophages and pro-inflammatory macrophages, IL-4 induced anti-inflammatory macrophages to exert higher activities of lipolysis, fatty acid oxidation (FAO) and oxidative phosphorylation (OXPHOS) [92].”
BackgroundReprogramming mitochondrial metabolism in macrophages as an anti‐inflammatory signal
Mills, E. L., & O'Neill, L. A. (2016) · European Journal of Immunology · doi:10.1002/eji.201445427 · Cited by 458 · cited 1×
“Enhancement of the aerobic glycolysis mediated by the mTOR/HIF-1 signaling pathway, polarized macrophages towards a pro-inflammatory phenotype [85,86].”
BackgroundGalli, A., Crabb, D. W., Ceni, E., Salzano, R., Mello, T., Svegliati–Baroni, G., Ridolfi, F., Trozzi, L., Surrenti, C., & Casini, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.33666 · Cited by 440 · cited 1×
“Activated HSCs may be reversed to a static phenotype, thus indicating that PPAR γ is able to regulate the expression of pro-inflammatory and profibrogenic genes [159,160].”
BackgroundRole of stearoyl-coenzyme A desaturase in regulating lipid metabolism
Flowers, M. T., & Ntambi, J. M. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282f9b54d · Cited by 438 · cited 1×
“In mouse liver, activation of PPAR β/δ can inhibit the expression of SREBP1c, which in turn was shown to attenuate liver steatosis [142].”
BackgroundFGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α Pathway
Potthoff, M. J., Boney-Montoya, J., Choi, M., He, T., Sunny, N. E., Satapati, S., Suino-Powell, K., Xu, H. E., Gerard, R. D., Finck, B. N., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.03.019 · Cited by 431
Bile Acids as Hormones: The FXR-FGF15/19 Pathway
Kliewer, S. A., & Mangelsdorf, D. J. (2015) · Digestive Diseases · doi:10.1159/000371670 · Cited by 424 · cited 1×
“FGF19 is an enterokine that reaches the liver via portal circulation and binds to the FGF receptor 4/β-klotho, which thereby represses bile acid synthesis and gluconeogenesis in liver [164].”
BackgroundCipriani, S., Mencarelli, A., Palladino, G., & Fiorucci, S. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m001602 · Cited by 416 · cited 1×
“In Zucker (fa/fa) rats, the FXR agonist obeticholic acid (OCA) activated FXR, eventually preventing steatosis, obesity, and insulin resistance [182].”
BackgroundStaels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414 · cited 1×
“In the liver, PPAR β/δ is expressed in hepatocytes, hepatic stellate cells (HSCs) and KCs, thus potentially participating in inflammation and fibrosis in NASH (Figure 2) [139].”
BackgroundDjouadi, F., Weinheimer, C. J., Saffitz, J. E., Pitchford, C., Bastin, J., Gonzalez, F. J., & Kelly, D. P. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3949 · Cited by 410 · cited 2×
“PPARα directly regulates the cellular uptake of FAs, which is the classical process of FAs decomposition to produce energy [126,127].”
BackgroundTsuchida, A., Yamauchi, T., Takekawa, S., Hada, Y., Ito, Y., Maki, T., & Kadowaki, T. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3358 · Cited by 409
Tran, S., Baba, I., Poupel, L., Dussaud, S., Moreau, M., Gélineau, A., Marcelin, G., Magréau-Davy, E., Ouhachi, M., Lesnik, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.003 · Cited by 400 · cited 1×
“More recent evidence suggests that Kupffer cells are lost during experimental steatohepatitis and replenished by monocyte derived Kupffer cells with similar, albeit more pro-inflammatory gene expression profiles [96,97].”
BackgroundThe Farnesoid X-receptor Is an Essential Regulator of Cholesterol Homeostasis
Lambert, G., Amar, M. J. A., Guo, G., Brewer, H. B., Gonzalez, F. J., & Sinal, C. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209525200 · Cited by 392 · cited 1×
“FXR-/mice show elevated triglyceride and cholesterol levels in serum, along with excessive lipid enrichment in the liver [178].”
BackgroundMorán‐Salvador, E., López‐Parra, M., García‐Alonso, V., Titos, E., Martínez‐Clemente, M., González‐Périz, A., López‐Vicario, C., Barak, Y., Arroyo, V., & Clària, J. (2011) · The FASEB Journal · doi:10.1096/fj.10-173716 · Cited by 389
Fatty acid oxidation in macrophage polarization
Nomura, M., Liu, J., Rovira, I. I., Gonzalez-Hurtado, E., Lee, J., Wolfgang, M. J., & Finkel, T. (2016) · Nature Immunology · doi:10.1038/ni.3366 · Cited by 386 · cited 3×
“Indeed, compared with naïve macrophages and pro-inflammatory macrophages, IL-4 induced anti-inflammatory macrophages to exert higher activities of lipolysis, fatty acid oxidation (FAO) and oxidative phosphorylation (OXPHOS) [92].”
BackgroundGawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., et al. (2021) · Hepatology · doi:10.1002/hep.31843 · Cited by 379
Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC
Grohmann, M., Wiede, F., Dodd, G. T., Gurzov, E. N., Ooi, G. J., Butt, T., Rasmiena, A. A., Kaur, S., Gulati, T., Goh, P. K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.053 · Cited by 373 · cited 1×
“Furthermore, oxidative stress during NASH significantly induced the exhaustion of tyrosine phosphatase, including tyrosine phosphatase non-receptor type 2 (PTPN2, also known as TCPTP) [31].”
BackgroundEnhanced free cholesterol, SREBP-2 and StAR expression in human NASH
Caballero, F., Fernández, A., De Lacy, A. M., Fernández-Checa, J. C., Caballería, J., & García-Ruiz, C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.016 · Cited by 368 · cited 1×
“Interestingly, free cholesterol is elevated in NASH livers in both humans and mice and has been proposed to be a lipotoxic DAMP, inducing NLRP3 activation and pyroptosis in Kupffer cells [40,74,75].”
BackgroundFrancque, S., Verrijken, A., Caron, S., Prawitt, J., Paumelle, R., Derudas, B., Lefebvre, P., Taskinen, M.-R., Van Hul, W., Mertens, I., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.019 · Cited by 357
Patel, K., Harrison, S. A., Elkhashab, M., Trotter, J. F., Herring, R., Rojter, S. E., Kayali, Z., Wong, V. W., Greenbloom, S., Jayakumar, S., et al. (2020) · Hepatology · doi:10.1002/hep.31205 · Cited by 347
Imajo, K., Fujita, K., Yoneda, M., Nozaki, Y., Ogawa, Y., Shinohara, Y., Kato, S., Mawatari, H., Shibata, W., Kitani, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.05.012 · Cited by 341 · cited 1×
“Indeed, steatosis induced by long-term feeding of high-fat diet (HFD) under experimental conditions in mice, increases hepatocyte susceptibility to cytokine-induced cell death [27].”
BackgroundVillablanca, E. J., Raccosta, L., Zhou, D., Fontana, R., Maggioni, D., Negro, A., Sanvito, F., Ponzoni, M., Valentinis, B., Bregni, M., et al. (2010) · Nature Medicine · doi:10.1038/nm.2074 · Cited by 335
Liver Macrophages: Old Dogmas and New Insights
Guillot, A., & Tacke, F. (2019) · Hepatology Communications · doi:10.1002/hep4.1356 · Cited by 335
Self-citationNonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316 · cited 1×
“Closing the loop, NR ligands, such as PPAR agonists, were shown to dampen inflammatory macrophages in NAFLD in addition to restoring metabolic homeostasis, thus offering a therapeutic link between correction of metabolic dysfunction and alleviation of inflammatory insults [22].”
BackgroundSelf-citationA positive feedback loop between RIP3 and JNK controls non‐alcoholic steatohepatitis
Gautheron, J., Vucur, M., Reisinger, F., Cardenas, D. V., Roderburg, C., Koppe, C., Kreggenwinkel, K., Schneider, A. T., Bartneck, M., Neumann, U. P., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201403856 · Cited by 314
Self-citationLefere, S., Puengel, T., Hundertmark, J., Penners, C., Frank, A. K., Guillot, A., de Muynck, K., Heymann, F., Adarbes, V., Defrêne, E., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.025 · Cited by 310
Self-citationCell Death in Liver Diseases: A Review
Shojaie, L., Iorga, A., & Dara, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249682 · Cited by 293 · cited 2×
“Several studies have shown that pyroptosis may play an important role in the development of NASH [63].”
BackgroundZhang, S., Wang, J., Liu, Q., & Harnish, D. C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.025 · Cited by 290 · cited 1×
“In MCD diet-fed mice, the FXR agonist WAY-362450 reduced liver inflammation and fibrogenesis without triglyceride enrichment [184,185].”
BackgroundRegulation of Carbohydrate Metabolism by the Farnesoid X Receptor
Stayrook, K. R., Bramlett, K. S., Savkur, R. S., Ficorilli, J., Cook, T., Christe, M. E., Michael, L. F., & Burris, T. P. (2005) · Endocrinology · doi:10.1210/en.2004-0965 · Cited by 288 · cited 1×
“In addition, FXR deficiency may also lead to insulin resistance [179,180].”
BackgroundIto, A., Hong, C., Rong, X., Zhu, X., Tarling, E. J., Hedde, P. N., Gratton, E., Parks, J., & Tontonoz, P. (2015) · eLife · doi:10.7554/elife.08009 · Cited by 281 · cited 2×
“In bone marrow-derived macrophages (BMDMs), the activation of LXR inhibited TLR2, TLR4, and TLR9 and related pathways, which resulted in anti-inflammatory features with less convergency of immune cells [188].”
BackgroundHarrison, S. A., Neff, G., Guy, C. D., Bashir, M. R., Paredes, A. H., Frias, J. P., Younes, Z., Trotter, J. F., Gunn, N. T., Moussa, S. E., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.08.004 · Cited by 280 · cited 1×
“However, aldafermin did not improve fibrosis stage in a biopsy-controlled phase 2b clinical trial in non-cirrhotic NASH patients, leading to the discontinuation of drug development in this indication [224].”
BackgroundNuclear receptors and nonalcoholic fatty liver disease
Cave, M. C., Clair, H. B., Hardesty, J. E., Falkner, K. C., Feng, W., Clark, B. J., Sidey, J., Shi, H., Aqel, B. A., McClain, C. J., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.03.002 · Cited by 279 · cited 1×
“master regulator of lipid synthesis, along with which SCD1 and FASN also act as regulator in liver metabolism [119].”
BackgroundIbrahim, S. H., Hirsova, P., & Gores, G. J. (2018) · Gut · doi:10.1136/gutjnl-2017-315691 · Cited by 278 · cited 1×
“According to evidence from mouse models, even exclusive hepatic cell death can trigger the development of NASH [34].”
BackgroundSafadi, R., Konikoff, F. M., Mahamid, M., Zelber-Sagi, S., Halpern, M., Gilat, T., Oren, R., Safadi, R., Konikoff, F. M., Hershkovitz, A., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.038 · Cited by 274 · cited 1×
“gov number NCT01094158 (accessed on 28 December 2021)) [237].”
BackgroundHarrison, S. A., Rossi, S. J., Paredes, A. H., Trotter, J. F., Bashir, M. R., Guy, C. D., Banerjee, R., Jaros, M. J., Owers, S., Baxter, B. A., et al. (2020) · Hepatology · doi:10.1002/hep.30590 · Cited by 262 · cited 2×
“Aldafermin or NGM282 is a humanized FGF19 analogue which significantly ameliorated histological features, imaging scores and serum markers in a phase 2b clinical trial in biopsy proven NASH patients (ClinicalTrials.gov (accessed on 28 December 2021) Identifier NCT02443116) [223].”
BackgroundKim, S. Y., Jeong, J.-M., Kim, S. J., Seo, W., Kim, M.-H., Choi, W.-M., Yoo, W., Lee, J.-H., Shim, Y.-R., Yi, H.-S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02325-2 · Cited by 256 · cited 1×
“For example, palmitic acid and TLR2 may synergistically induce activation of inflammasomes in KCs/macrophages and polarize KCs/macrophages towards pro-inflammatory phenotypes [98].”
BackgroundLeroux, A., Ferrere, G., Godie, V., Cailleux, F., Renoud, M.-L., Gaudin, F., Naveau, S., Prévot, S., Makhzami, S., Perlemuter, G., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.028 · Cited by 246
A subset of Kupffer cells regulates metabolism through the expression of CD36
Blériot, C., Barreby, E., Dunsmore, G., Ballaire, R., Chakarov, S., Ficht, X., De Simone, G., Andreata, F., Fumagalli, V., Guo, W., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.006 · Cited by 236 · cited 1×
“KC2 were numerically expanded, and specific depletion of this subset reversed obesity and steatosis in mice [80].”
BackgroundMihm, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103104 · Cited by 232 · cited 1×
“Dying hepatocytes release DAMPs, which activate pattern recognition receptors (PRRs) on KCs and induce the recruitment of immune cells (such as monocytes and neutrophils), thereby enhancing inflammation [112].”
BackgroundMetabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators
Piccinin, E., Villani, G., & Moschetta, A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0089-3 · Cited by 231 · cited 1×
“PPAR γ expression in the healthy liver is low, compared to adipose tissue, but in both patients and experimental animal models, elevated transcription levels of PPAR γ in the liver was a feature of steatosis [151,152].”
BackgroundLytic cell death in metabolic liver disease
Gautheron, J., Gores, G. J., & Rodrigues, C. M. P. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.001 · Cited by 225 · cited 1×
“In recent years, a better understanding of cell death mechanisms has expanded the number of known processes involved in metabolic liver diseases, from apoptosis to mitochondrial permeability transition (MPT)-driven necrosis, and necroptosis, autophagic apoptosis, and pyroptosis [38].”
BackgroundRatziu, V., de Guevara, L., Safadi, R., Poordad, F., Fuster, F., Flores-Figueroa, J., Arrese, M., Fracanzani, A. L., Ben Bashat, D., Lackner, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01495-3 · Cited by 222 · cited 2×
“Based on those results the ARREST study analysed efficacy of aramchol in a total of 247 patients with biopsy confirmed NASH (NAS ≥ 4), overweight or obesity and prediabetes or type 2 diabetes (ClinicalTrials.gov (accessed on 28 December 2021) Identifier NCT02279524) [238].”
BackgroundAfonso, M. B., Rodrigues, P. M., Carvalho, T., Caridade, M., Borralho, P., Cortez-Pinto, H., Castro, R. E., & Rodrigues, C. M. P. (2015) · Clinical Science · doi:10.1042/cs20140732 · Cited by 221 · cited 1×
“Furthermore, extensive necroptotic changes were revealed in human NASH livers [36,52].”
BackgroundZhang, Y., Breevoort, S. R., Angdisen, J., Fu, M., Schmidt, D. R., Holmstrom, S. R., Kliewer, S. A., Mangelsdorf, D. J., & Schulman, I. G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59817 · Cited by 213 · cited 1×
“However, LXR at the same time promotes cholesterol efflux, reduces cholesterol synthesis and uptake [161,187].”
BackgroundInterleukin-1 as Innate Mediator of T Cell Immunity
Van Den Eeckhout, B., Tavernier, J., & Gerlo, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.621931 · Cited by 213
Targeting nuclear receptors for the treatment of fatty liver disease
Tanaka, N., Aoyama, T., Kimura, S., & Gonzalez, F. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.011 · Cited by 212 · cited 2×
“management, which may play a critical role in the pathogenesis of NAFLD [14].”
BackgroundItoh, M., Kato, H., Suganami, T., Konuma, K., Marumoto, Y., Terai, S., Sakugawa, H., Kanai, S., Hamaguchi, M., Fukaishi, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082163 · Cited by 211
Harrison, S. A., Alkhouri, N., Davison, B. A., Sanyal, A., Edwards, C., Colca, J. R., Lee, B. H., Loomba, R., Cusi, K., Kolterman, O., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.023 · Cited by 211
Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
Rinella, M. E., Tacke, F., Sanyal, A. J., & Anstee, Q. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.019 · Cited by 209
Self-citationYe, D., Li, F. Y. L., Lam, K. S. L., Li, H., Jia, W., Wang, Y., Man, K., Lo, C. M., Li, X., & Xu, A. (2012) · Gut · doi:10.1136/gutjnl-2011-300269 · Cited by 206
Jain, M. R., Giri, S. R., Bhoi, B., Trivedi, C., Rath, A., Rathod, R., Ranvir, R., Kadam, S., Patel, H., Swain, P., et al. (2018) · Liver International · doi:10.1111/liv.13634 · Cited by 206
Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis
Sun, X., Seidman, J. S., Zhao, P., Troutman, T. D., Spann, N. J., Que, X., Zhou, F., Liao, Z., Pasillas, M., Yang, X., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.10.014 · Cited by 204
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204 · cited 3×
“Novel strategies that have been proposed include either combination therapy of agents targeting multiple components, such as inflammation and metabolism, or single drugs with multiple targets [13].”
BackgroundInfluentialStienstra, R., Netea-Maier, R. T., Riksen, N. P., Joosten, L. A. B., & Netea, M. G. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.001 · Cited by 194
Caspase-1 as a Central Regulator of High Fat Diet-Induced Non-Alcoholic Steatohepatitis
Dixon, L. J., Flask, C. A., Papouchado, B. G., Feldstein, A. E., & Nagy, L. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056100 · Cited by 188
Cyclophilin D in mitochondrial pathophysiology
Giorgio, V., Soriano, M. E., Basso, E., Bisetto, E., Lippe, G., Forte, M. A., & Bernardi, P. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2009.12.006 · Cited by 180
Venteclef, N., Jakobsson, T., Ehrlund, A., Damdimopoulos, A., Mikkonen, L., Ellis, E., Nilsson, L.-M., Parini, P., Jänne, O. A., Gustafsson, J.-Å., et al. (2010) · Genes & Development · doi:10.1101/gad.545110 · Cited by 178
A self-sustained loop of inflammation-driven inhibition of beige adipogenesis in obesity
Chung, K.-J., Chatzigeorgiou, A., Economopoulou, M., Garcia-Martin, R., Alexaki, V. I., Mitroulis, I., Nati, M., Gebler, J., Ziemssen, T., Goelz, S. E., et al. (2017) · Nature Immunology · doi:10.1038/ni.3728 · Cited by 175
Hepatic lipid homeostasis by peroxisome proliferator-activated receptor gamma 2
Lee, Y. K., Park, J. E., Lee, M., & Hardwick, J. P. (2018) · Liver Research · doi:10.1016/j.livres.2018.12.001 · Cited by 173 · cited 1×
“Particularly, the hepatic expression of PPAR γ2 was shown to be induced by consumption of high caloric food [153].”
BackgroundAlvarez-Sola, G., Uriarte, I., Latasa, M. U., Fernandez-Barrena, M. G., Urtasun, R., Elizalde, M., Barcena-Varela, M., Jiménez, M., Chang, H. C., Barbero, R., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312975 · Cited by 164 · cited 1×
“Intestinal FXR signaling and induction of FGF15/19 were shown to dampen steatosis, inflammation, and fibrosis as mice deficient in FGF15 fed a HFD had severe steatohepatitis [174,175].”
BackgroundLee, Y. J., Ko, E. H., Kim, J. E., Kim, E., Lee, H., Choi, H., Yu, J. H., Kim, H. J., Seong, J.-K., Kim, K.-S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203218109 · Cited by 163
Zhuang, H., Lv, Q., Zhong, C., Cui, Y., He, L., Zhang, C., & Yu, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.649463 · Cited by 161
Pockros, P. J., Fuchs, M., Freilich, B., Schiff, E., Kohli, A., Lawitz, E. J., Hellstern, P. A., Owens‐Grillo, J., Van Biene, C., Shringarpure, R., et al. (2019) · Liver International · doi:10.1111/liv.14209 · Cited by 160 · cited 2×
“gov (accessed on 28 December 2021) Identifier NCT02633956) [233].”
BackgroundCaspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis
Dixon, L. J., Berk, M., Thapaliya, S., Papouchado, B. G., & Feldstein, A. E. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.45 · Cited by 158
Hepatic FXR: key regulator of whole-body energy metabolism
Teodoro, J. S., Rolo, A. P., & Palmeira, C. M. (2011) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2011.07.002 · Cited by 157 · cited 5×
“In a phase 2 clinical trial (EVIDENCES IV, ClinicalTrials.gov (accessed on 28 December 2021) Identifier: NCT03061721), saroglitazar was tested in 106 patients with NAFLD/NASH for 16 weeks [217].”
BackgroundInfluentialLamichane, S., Dahal Lamichane, B., & Kwon, S.-M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040949 · Cited by 156 · cited 1×
“Peroxisome proliferator-activated receptors (PPARs) represent a group of nuclear hormone receptors, which are expressed in various tissues influencing multiple systemic and metabolically relevant processes (β-oxidation of fatty acids, lipid transport, keto- or gluconeogenesis) [123].”
BackgroundZhou, M., Learned, R. M., Rossi, S. J., DePaoli, A. M., Tian, H., & Ling, L. (2017) · Hepatology Communications · doi:10.1002/hep4.1108 · Cited by 152 · cited 1×
“Intestinal FXR signaling and induction of FGF15/19 were shown to dampen steatosis, inflammation, and fibrosis as mice deficient in FGF15 fed a HFD had severe steatohepatitis [174,175].”
BackgroundTNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice
Wandrer, F., Liebig, S., Marhenke, S., Vogel, A., John, K., Manns, M. P., Teufel, A., Itzel, T., Longerich, T., Maier, O., et al. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2411-6 · Cited by 152 · cited 1×
“Notably, during NASH progression, the suppression of TNF-induced signaling was recently shown to reduce cell death and liver damage, thereby reducing liver steatosis and fibrosis, highlighting a crucial role of inflammatory modulation in hepatic cell death mechanisms [37].”
BackgroundGirroir, E. E., Hollingshead, H. E., He, P., Zhu, B., Perdew, G. H., & Peters, J. M. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.086 · Cited by 150
The potential role of necroptosis in inflammaging and aging
Royce, G. H., Brown‐Borg, H. M., & Deepa, S. S. (2019) · GeroScience · doi:10.1007/s11357-019-00131-w · Cited by 146 · cited 1×
“Multiple studies revealed that necroptosis was the main source of inflammatory modulation in disease and the genetic or pharmacologic inhibition of necroptosis could be a promising therapeutic modulation [58].”
BackgroundMajdi, A., Aoudjehane, L., Ratziu, V., Islam, T., Afonso, M. B., Conti, F., Mestiri, T., Lagouge, M., Foufelle, F., Ballenghien, F., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.008 · Cited by 146 · cited 2×
“Studies have shown that necroptosis was significantly increased in the HFD-fed mouse model [50,51].”
BackgroundThe role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Chow, M. D., Lee, Y.-H., & Guo, G. L. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.04.004 · Cited by 140 · cited 1×
“Farnesoid X receptor (FXR) is the most important NR for the maintenance of bile acid (BA) synthesis [162,163].”
BackgroundGuo, B., Huang, X., Lee, M. R., Lee, S. A., & Broxmeyer, H. E. (2018) · Nature Medicine · doi:10.1038/nm.4477 · Cited by 140
Hellemans, K., Michalik, L., Dittie, A., Knorr, A., Rombouts, K., de Jong, J., Heirman, C., Quartier, E., Schuit, F., Wahli, W., et al. (2003) · Gastroenterology · doi:10.1053/gast.2003.50015 · Cited by 137
Ahn, S. B., Jang, K., Jun, D. W., Lee, B. H., & Shin, K. J. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3289-x · Cited by 136 · cited 2×
“In NAFLD, LXR is thought to have opposing roles: while LXR expression was reported to increase with severity of NASH, potentially driving obesity and steatosis, LXR was also shown to suppress inflammation and improve hypercholesterolemia [188,189].”
BackgroundChatterjee, S., Ganini, D., Tokar, E. J., Kumar, A., Das, S., Corbett, J., Kadiiska, M. B., Waalkes, M. P., Diehl, A. M., & Mason, R. P. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.035 · Cited by 134 · cited 16×
“Dying hepatocytes release DAMPs, which activate pattern recognition receptors (PRRs) on KCs and induce the recruitment of immune cells (such as monocytes and neutrophils), thereby enhancing inflammation [112].”
BackgroundInfluentialWettstein, G., Luccarini, J., Poekes, L., Faye, P., Kupkowski, F., Adarbes, V., Defrêne, E., Estivalet, C., Gawronski, X., Jantzen, I., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1057 · Cited by 132 · cited 1×
“In addition to influencing steatosis, PPARα exerts anti-inflammatory properties, mainly by suppressing pro-inflammatory genes [134].”
BackgroundBeaven, S. W., Wroblewski, K., Wang, J., Hong, C., Bensinger, S., Tsukamoto, H., & Tontonoz, P. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.053 · Cited by 131 · cited 1×
“LXR deficiency of mice favors liver fibrogenesis and lipid accumulation [198,199].”
BackgroundHiuge, A., Tenenbaum, A., Maeda, N., Benderly, M., Kumada, M., Fisman, E. Z., Tanne, D., Matas, Z., Hibuse, T., Fujita, K., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000256469.06782.d5 · Cited by 122 · cited 1×
“On the contrary, it was demonstrated that adiponectin secretion and adiponectin receptor (AdipoR-1 and -2) expression was increased upon PPARα activation in adipocytes [132].”
BackgroundMorán‐Salvador, E., Titos, E., Rius, B., González‐Périz, A., García‐Alonso, V., López‐Vicario, C., Miquel, R., Barak, Y., Arroyo, V., & Clària, J. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.06.023 · Cited by 121
Bieghs, V., Verheyen, F., van Gorp, P. J., Hendrikx, T., Wouters, K., Lütjohann, D., Gijbels, M. J. J., Febbraio, M., Binder, C. J., Hofker, M. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034378 · Cited by 120 · cited 1×
“KCs can engulf lipoproteins through receptors such as scavenger receptor CD36, inducing a pro-inflammatory phenotype, eventually forming pro-inflammatory foam-like macrophages [108].”
BackgroundCariello, M., Piccinin, E., & Moschetta, A. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.01.012 · Cited by 120 · cited 2×
“However, LXR at the same time promotes cholesterol efflux, reduces cholesterol synthesis and uptake [161,187].”
BackgroundPark, J., Jeong, G., Kim, S. J., Kim, M. K., & Park, S. M. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04758.x · Cited by 118
Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease
Zarei, M., Barroso, E., Palomer, X., Dai, J., Rada, P., Quesada-López, T., Escolà-Gil, J. C., Cedó, L., Zali, M. R., Molaei, M., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2017.12.008 · Cited by 117
Cyclophilin inhibition as potential therapy for liver diseases
Naoumov, N. V. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.008 · Cited by 115
Role of aramchol in steatohepatitis and fibrosis in mice
Iruarrizaga‐Lejarreta, M., Varela‐Rey, M., Fernández‐Ramos, D., Martínez‐Arranz, I., Delgado, T. C., Simon, J., Gutiérrez‐de Juan, V., delaCruz‐Villar, L., Azkargorta, M., Lavin, J. L., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1107 · Cited by 113 · cited 1×
“Those beneficial effects were observed in several experimental models leading to further assessment in clinical studies [235,236].”
BackgroundRole of farnesoid X receptor and bile acids in alcoholic liver disease
Manley, S., & Ding, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2014.12.011 · Cited by 112 · cited 1×
“In MCD diet-fed mice, the FXR agonist WAY-362450 reduced liver inflammation and fibrogenesis without triglyceride enrichment [184,185].”
BackgroundAfonso, M. B., Rodrigues, P. M., Mateus‐Pinheiro, M., Simão, A. L., Gaspar, M. M., Majdi, A., Arretxe, E., Alonso, C., Santos‐Laso, Á., Jiménez-Agüero, R., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-321767 · Cited by 112
Zizzo, G., & Cohen, P. L. (2015) · Journal of Inflammation · doi:10.1186/s12950-015-0081-4 · Cited by 110
Kumar, D. P., Caffrey, R., Marioneaux, J., Santhekadur, P. K., Bhat, M., Alonso, C., Koduru, S. V., Philip, B., Jain, M. R., Giri, S. R., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-66458-z · Cited by 110
Tao, L., Yi, Y., Chen, Y., Zhang, H., Jie, J., Zhang, W., Xu, Q., Li, Y., Ørning, P., Lien, E., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-00668-w · Cited by 110 · cited 2×
“The kinase activity of RIP1 in NASH-associated cell death was recently investigated [57].”
BackgroundLi, Z., Lin, H., Yang, S., & Diehl, A. M. (2002) · Gastroenterology · doi:10.1053/gast.2002.35997 · Cited by 109 · cited 16×
“Dying hepatocytes release DAMPs, which activate pattern recognition receptors (PRRs) on KCs and induce the recruitment of immune cells (such as monocytes and neutrophils), thereby enhancing inflammation [112].”
BackgroundInfluentialWouters, K., van Bilsen, M., van Gorp, P. J., Bieghs, V., Lütjohann, D., Kerksiek, A., Staels, B., Hofker, M. H., & Shiri-Sverdlov, R. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.046 · Cited by 109 · cited 1×
“In APO-E2 knock-in mice, LXR agonist treatment translated into depressed levels of cholesterol and inflammation, but elevated liver triglyceride levels [193,194].”
BackgroundMacrophages, rather than DCs, are responsible for inflammasome activity in the GM-CSF BMDC model
Erlich, Z., Shlomovitz, I., Edry‐Botzer, L., Cohen, H., Frank, D. O., Wang, H., Lew, A. M., Lawlor, K. E., Zhan, Y., Vince, J. E., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0313-5 · Cited by 108
The Cholesterol Derivative 27-Hydroxycholesterol Reduces Steatohepatitis in Mice
Bieghs, V., Hendrikx, T., van Gorp, P. J., Verheyen, F., Guichot, Y. D., Walenbergh, S. M. A., Jeurissen, M. L. J., Gijbels, M. J., Rensen, S. S., Bast, A., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.062 · Cited by 100 · cited 1×
“Notably, in SREBP1c-defecient KCs, 27-hydroxycholesterol treatment reduced HFD-induced steatosis, leukocyte aggregation and pro-inflammatory gene expression [195].”
BackgroundNuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease
Fuchs, C., Traussnigg, S., & Trauner, M. (2016) · Seminars in Liver Disease · doi:10.1055/s-0036-1571296 · Cited by 100 · cited 1×
“PPAR β/δ promotes fatty acid β-oxidation in extrahepatic tissues, is mainly expressed in adipose tissue acting as insulin sensitizer and prevents ectopic fat storage by induction of triglyceride formation of free fatty acids [137,138].”
BackgroundVespasiani‐Gentilucci, U., Carotti, S., Perrone, G., Mazzarelli, C., Galati, G., Onetti‐Muda, A., Picardi, A., & Morini, S. (2015) · Liver International · doi:10.1111/liv.12531 · Cited by 99
The NLRP3 inflammasome in alcoholic and nonalcoholic steatohepatitis
Knorr, J., Wree, A., Tacke, F., & Feldstein, A. E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708540 · Cited by 99
Self-citationTrained Immunity: Long-Term Adaptation in Innate Immune Responses
Tercan, H., Riksen, N. P., Joosten, L. A. B., Netea, M. G., & Bekkering, S. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314212 · Cited by 97
Jha, P., Claudel, T., Baghdasaryan, A., Mueller, M., Halilbasic, E., Das, S. K., Lass, A., Zimmermann, R., Zechner, R., Hoefler, G., et al. (2014) · Hepatology · doi:10.1002/hep.26732 · Cited by 96 · cited 1×
“Compared with wild-type mice, they were more likely to develop steatohepatitis under the stimulation of LPS and MCD diet [136].”
BackgroundImpaired SUMOylation of nuclear receptor LRH-1 promotes nonalcoholic fatty liver disease
Stein, S., Lemos, V., Xu, P., Demagny, H., Wang, X., Ryu, D., Jiménez, V., Bosch, F., Lüscher, T. F., Oosterveer, M. H., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci85499 · Cited by 88 · cited 2×
“Recently, the role of LRH-1 SUMOylation was implicated in the development of NAFLD [203].”
BackgroundInnate immune cells in the adipose tissue
Chung, K., Nati, M., Chavakis, T., & Chatzigeorgiou, A. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9451-6 · Cited by 88
Yu, J. Q., Zhang, S., Chu, E. S., Go, M. Y. Y., Lau, R. H. Y., Zhao, J., Wu, C., Tong, L., Zhao, J., Poon, T. C. W., et al. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.02.006 · Cited by 84
New drugs for NAFLD: lessons from basic models to the clinic
Reimer, K. C., Wree, A., Roderburg, C., & Tacke, F. (2019) · Hepatology International · doi:10.1007/s12072-019-10001-4 · Cited by 84 · cited 1×
“In this context, combinatorial therapeutic strategies targeting multiple pathways in parallel appear attractive and potentially bear significant advantages over single drug treatments (Figure 2) [210,211].”
BackgroundSelf-citationKostadinova, R., Montagner, A., Gouranton, E., Fleury, S., Guillou, H., Dombrowicz, D., Desreumaux, P., & Wahli, W. (2012) · Cell & Bioscience · doi:10.1186/2045-3701-2-34 · Cited by 83
Ballestri, S., Nascimbeni, F., Romagnoli, D., Baldelli, E., & Lonardo, A. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0306-9 · Cited by 80
Lalloyer, F., Wouters, K., Baron, M., Caron, S., Vallez, E., Vanhoutte, J., Baugé, E., Shiri-Sverdlov, R., Hofker, M., Staels, B., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.220525 · Cited by 76 · cited 1×
“In APO-E2 knock-in mice, LXR agonist treatment translated into depressed levels of cholesterol and inflammation, but elevated liver triglyceride levels [193,194].”
BackgroundAn update on the recent advances in antifibrotic therapy
Tacke, F., & Weiskirchen, R. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1530110 · Cited by 76 · cited 1×
“As awareness of NAFLD is increasing globally [206], ongoing preclinical and clinical studies provided various pathomechanistic insights into disease development and progression, identifying many new potential drug targets [24,207,208].”
BackgroundSelf-citationFarnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration
Li, G., & L. Guo, G. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.01.005 · Cited by 75
Cited by
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
Self-citationPeiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Self-citationMetabolic reprogramming in liver fibrosis
Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432
Self-citationAn integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Self-citationKamata, S., Honda, A., & Ishii, I. (2023) · Biomolecules · doi:10.3390/biom13081264 · Cited by 81
Metadata
- Authors
- Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M.
- Affiliations
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Corresponding author
- Tacke, Frank
- Peiseler, Moritz
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-02-28
- Volume
- 23
- Issue
- 5
- Pages
- 2668
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8910763
- OpenAlex
- W4214523533
- Cited by
- 95
- References
- 238
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 30 · 2023: 22 · 2022: 18
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Deutsche Forschungsgemeinschaft (SFB/TRR296, CRC1382)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (CSP 21-1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, nuclear receptors, peroxisome proliferator-activated receptors, liver inflammation, liver fibrosis, metabolic syndrome, insulin resistance, immunometabolism, hepatocyte death, lipotoxicity, gut dysbiosis, hepatic macrophages, hepatocellular carcinoma, combination therapy
- MeSH terms
- Diabetes Mellitus, Type 2, Fibrosis, Carcinoma, Hepatocellular, Humans, Inflammation, Liver, Liver Neoplasms, Receptors, Cytoplasmic and Nuclear, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.